NbN C&A 3.1.1

European College of Neuropsychopharmacology (ECNP) ❘ 프리웨어 ❘
iOS

Report a Problem

이것은 다운로드하여 양식을하지 않습니다!

이 UpdateStar 프로그램이 데이터베이스는 사용자에 의해 관리되고, 사용자에게있습니다.
귀하의 지원과 함께, 당신은 다른 모든 사용자를 자신의 소프트웨어를 설치하지 않도록 도울 수있습니다 - - 날짜입니다. 그하거나 최신 잘못된되지 않은 필드를 기입하십시오. 우리는 확인하고 최대한 빨리 당신의 공헌을 평가합니다.
UpdateStar 지원 해 주셔서 감사합니다!

제목 :

카테고리 :

요구 사항 :

Android

iOS

Windows

Mac

Linux

라이센스 :

제작사 :

제작사 홈페이지 :

설명 :

The NbN was developed in response to the recognition that the existing pharmacological nomenclature for psychotropic medications does not adequately reflect current scientific understanding nor support clinicians in neuroscience-informed prescribing practices. Frequently, clinicians prescribe "antidepressants" for anxiety disorders or "second-generation antipsychotics" for depression, which can lead to confusion and a lack of clarity regarding the underlying mechanisms involved.

The primary objective of NbN is to integrate recent advances in neuroscience into the terminology used for psychotropic medications. Its scope encompasses all drugs with central nervous system (CNS) indications, aiming to facilitate clinicians' identification of the most appropriate subsequent neuropsychopharmacological interventions based on a more precise understanding of drug action.

This proposed nomenclature endeavors to accurately reflect the current state of pharmacological knowledge; however, it acknowledges that it may not represent the definitive scientific consensus. The assembled taskforce deliberately chose to present a scientific interpretation rooted in the latest evidence rather than await absolute conclusions. This approach recognizes the urgent need for effective treatment in clinical settings, emphasizing that patient care cannot be delayed pending complete scientific certainty.

Consequently, this nomenclature is founded upon key considerations:
<ul>
<li>The imperative to treat patients promptly</li>
<li>The integration of contemporary neuroscience insights</li>
<li>The expert judgment of taskforce members</li>
<li>Recognition that pediatric populations are still developing, thus developmental factors such as hepatic and renal function and brain maturation must influence medication use and dosing</li>
</ul>

In developing NbN, emphasis has been placed on pharmacology and mechanisms of action. The nomenclature reflects current understanding of neurotransmitter systems, molecular targets, and pathways involved in psychotropic drug effects. Four clinically pertinent dimensions are incorporated:
<ol>
<li>Approved indications: Based on major regulatory bodies’ recommendations (e.g., FDA, EMA) applicable to specific age groups.</li>
<li>Efficacy and side effects: Highlighting instances where drugs lack formal approval for certain indications but are supported by evidence such as expert guidelines. The side effects section focuses on serious, life-threatening, or prevalent adverse effects.</li>
<li>Practical notes: Summarized clinical insights filtered through expert analysis.</li>
<li>Neurobiology: Derived from empirical data, providing a biological context for the medication’s action.</li>
</ol>

For those interested in further details regarding pharmacology, a direct link to the IUPHAR website—our collaborating partner—is provided for in-depth information.

This initiative is ongoing; we anticipate that gaps and omissions will be identified over time. Feedback from users, combined with responses from colleagues, emerging research reports, and new scientific findings, will inform subsequent updates to enhance the nomenclature’s accuracy and utility.

FiN N aims to embed cutting-edge neuroscience within a coherent and comprehensive naming framework for pediatric psychopharmacology. The taskforce hopes this system will support clinicians in making well-informed decisions regarding psychopharmacological treatment strategies and elucidate the rationale behind prescribing choices.

태그:

간략한 설명 :

설치된 버전을 알 수없는?

현재 버전 :

다운로드 URL :

직접 다운로드 URL :

구매 URL :

아이콘의 URL :

스크린샷 1 홈페이지 :

스크린샷 2 홈페이지 :

스크린샷 3 홈페이지 :

스크린샷 4 홈페이지 :

패드 파일 URL :

코멘트 :

귀하의 이메일 :

뉴스 :

제발, 우리가 여러분의 공헌에 대해 우리는 질문해야 연락을 드릴 수있습니다 귀하의 이메일 주소를 입력하십시오. 우리는 제 3 자에게 귀하의 전자 - 메일 주소를 공유하지 않습니다.

스크린샷 (클릭) 큰 볼

가장 인기있는 다운로드

	UpdateStar Premium Edition UpdateStar Premium Edition으로 소프트웨어를 최신 상태로 유지하는 것이 그 어느 때보다 쉬워졌습니다!
	Google Chrome 빠르고 다재다능한 웹 브라우저
	Microsoft Edge 웹 브라우징의 새로운 표준
	Microsoft Visual C++ 2015 Redistributable Package Microsoft Visual C++ 2015 재배포 가능 패키지로 시스템 성능을 향상시키십시오!
	Microsoft OneDrive Microsoft OneDrive로 파일 관리 간소화
	Microsoft Visual C++ 2010 Redistributable Visual C++ 응용 프로그램 실행을 위한 필수 구성 요소

브라 우즈

절대로 다시 UpdateStar NbN C&A에 대한 업데이 트를 그리워

현재 뉴스

	Kaspersky Password Manager Kaspersky Password Manager로 비밀번호를 보호하세요!
	Mozilla Maintenance Service Mozilla 유지 관리 서비스를 통해 Mozilla 소프트웨어를 원활하게 실행하십시오.
	AIMP AIMP로 음악 경험을 향상시키십시오!
	Google Chrome 빠르고 다재다능한 웹 브라우저
	Java Update Oracle의 Java Update를 통해 최신 상태 유지
	EPSON Event Manager EPSON Event Manager로 이벤트 계획 간소화

NbN C&A 3.1.1

스크린샷 (클릭) 큰 볼

관련

APA eBooks

Case Files Psychiatry, 6e

Columbia Psychiatry Pathways

CURRENT Dx Tx Psychiatry

DSM-5-TR® Diagnostic Criteria

ICD-11

최신 리뷰

가장 인기있는 다운로드

브라 우즈

최신 업데이트

usbipd-win 4.3

cTrader 5.7.14.51420

Orbex Global 4

DCTools 1.2.6

VYPN 1.5.4

FDRS 48.4.10

최신 소식

PeaZip 11.2.0 Released With Overhauled Shortcuts

Internet Download Manager 6.43 Build 5 Released

Brave Browser 1.92.138 Available

Wise Care 365 Update Released

qBittorrent 5.2.3 Update Fixes WebUI, RSS, and Torrent Handling Bugs

AnyDesk 9.7.9 Released